Intercept Pharmaceut (ICPT) Is It Worthy for Investors?


(NASDAQ:ICPT) in a research report report published on Thursday, September 14th. The stock's last price was higher from the average trading price of 50 days recorded at $0.82 while enlarging the period to 200 trading days, the average price was $2.51. Jefferies Group LLC reaffirmed a "buy" rating and set a $275.00 price target on shares of Intercept Pharmaceuticals in a report on Sunday, July 30th. Outstanding shares refer to a company's stock presently held by all its shareholders, counting share blocks held by institutional shareholders and restricted shares owned by the company's officers and insiders.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 16.43% on Friday, reaching $61.59. On Tuesday, September 22 the stock rating was upgraded by Vetr to "Strong-Buy". Four analysts have rated the stock with a sell rating, four have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock.

Intercept Pharmaceut (NASDAQ:ICPT) as of recent trade, has shown weekly downbeat performance of -15.68% which was maintained at -31.18% in 1-month period.

About 50,947 shares traded. The company has a 50-day moving average price of $106.75 and a 200 day moving average price of $115.74. The insider now holds 570,284 shares of Intercept Pharmaceuticals, Inc. The company has market cap of $1.60 billion. Cowen & Co maintained Intercept Pharmaceuticals Inc (NASDAQ:ICPT) on Monday, June 12 with "Buy" rating. Revenue during the quarter was $30.89 million, representing 460% growth from $5.52 million in year-ago quarter. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. During the same quarter in the prior year, the company earned ($5.17) EPS. If you are viewing this story on another site, it was copied illegally and republished in violation of USA and worldwide trademark & copyright law. Moreover, Guggenheim Limited has 0.01% invested in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). It increased, as 11 investors sold Intercept Pharmaceuticals Inc shares while 40 reduced holdings. The stock was sold at an average price of $117.43, for a total transaction of $146,787.50. Following the completion of the sale, the chief executive officer now directly owns 611,718 shares in the company, valued at $80,012,714.40. Also, CFO Sandip Kapadia sold 1,431 shares of the stock in a transaction dated Monday, July 3rd. This will give analytical advantage to a shorter-term trader since it pursues the price more intimately, and consequently produces less "lag" as comparison to the longer-term moving average. WFG Advisors LP now owns 888 shares of the biopharmaceutical company's stock worth $108,000 after purchasing an additional 125 shares during the last quarter. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. $187.99's average target is 109.72% above currents $89.64 stock price.

US Considering Shooting Down a North Korean Missile
It would also weaken the worldwide commitment to maintain sanctions against Pyongyang and could spark a global nuclear buildup. South Korea has raised the possibility of reintroducing nuclear weapons to the peninsula.

Multiple company employees have indulged in significant insider trading.

Several large investors have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC increased its holdings in shares of Intercept Pharmaceuticals by 1.8% in the second quarter. During the same quarter in the previous year, the company posted ($3.14) earnings per share.

WARNING: "Intercept Pharmaceuticals (ICPT) Earning Somewhat Favorable News Coverage, Report Finds" was first reported by Equities Focus and is the property of of Equities Focus. Of those holders, 91 had increased positions amounting to 1.1 million shares, 64 had decreased positions amounting to 1.41 million shares, and 23 holders have a held position accounting for 18.28 million shares. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company's stock worth $118,000 after acquiring an additional 132 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Intercept Pharmaceuticals by 14.4% in the first quarter. State Street Corp now owns 805,550 shares of the biopharmaceutical company's stock valued at $91,110,000 after buying an additional 54,523 shares during the last quarter. Rhumbline Advisers reported 0.01% in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company's stock worth $157,000 after acquiring an additional 730 shares during the last quarter.